Labcorp Holdings Inc. (LH) Stock: Price, Forecast & Analyst Target
Labcorp Holdings Inc. (LH) — MoonshotScore 71/100 (Strong band), calculated Oct 4, 2026. Price $308.49 (+1.28%), as of the Oct 2, 2026 trading session; market cap $25.3B. Expected results Oct 27, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 178.42× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 27, 2026
Labcorp Holdings Inc. · LH · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Labcorp sells diagnostic and research laboratory services to clinicians, healthcare facilities, drug developers, investigators, and patients; it is not merely a manufacturer of laboratory tests. The case rests on whether rising laboratory demand and improving profit conversion can outweigh heavy debt and the sharp contraction in readily available cash.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Labcorp Holdings (LH)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, though the balance sheet is only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Rising.
- quarterly revenue $3.73B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 7 of 8
- expected results Oct 27, 2026
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 70 | Strong | |
| 71 | Strong | |
| 70 | Strong | |
| 70 | Strong | |
| 71 | Strong | |
| 71 | Strong |
The score was 71 in the stored Oct 3, 2026 snapshot and remains 71 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $308.49 | |
| Change on the day | +1.28% | |
| 52-week range | $244.52–$341.80 | |
| Market capitalisation | $25.3B | |
| Price / earnings (trailing) | 25.35 | |
| Shares traded on the day | 586.9K | |
| Beta (volatility vs the S&P 500) | 0.85 | |
| Dividends per share (last 12 months) | $2.88 | |
| Dividend yield (last 12 months) | 0.93% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
On today's webcast, we will focus on our adjusted or non-GAAP results for the second quarter of 2026, our capital allocation strategy and our updated financial guidance for the full year 2026.
Dewey Steadman · Statement from
We continue to expect our full year adjusted tax rate to be approximately 23%.
Julia Wang · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Labcorp Holdings (LH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 30, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the LH film — every key number, told as a short cinematic story
~2 min · open the film
What is Labcorp Holdings (LH), and what does it report?
Short answer · as of
Labcorp processes clinical testing for patient care while also providing laboratory services used in pharmaceutical research and development.
Research dated 2026-09-12.
Labcorp processes clinical testing for patient care while also providing laboratory services used in pharmaceutical research and development. Demand therefore comes from medical testing activity and drug-development programs, making the company broader than its diagnostics classification suggests.
Companywide revenue combines activities with different demand drivers. Lab Corp Diagnostics accounts for most disclosed segment revenue, while management separately discusses Central Labs and Early Development, so the consolidated result is not a pure measure of routine patient testing.
What do the latest results show for Labcorp Holdings (LH)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $3.73B.
Research dated 2026-09-12.
The latest period extended revenue growth and produced stronger gross profit, operating profit, net income, and diluted earnings than the preceding period. Revenue and adjusted earnings also cleared market estimates, continuing a pattern in which adjusted earnings have exceeded expectations even when revenue occasionally missed.
Management maintained its free-cash-flow outlook and still expects Central Labs to grow faster than Early Development. That distinction matters: the reported improvement is visible in the financial statements, while the expected growth mix remains management guidance rather than an accomplished result.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $3.73B Jun 30, 2026
- Latest quarter · SG&A
- $577.20M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $451.60M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $3.73B | Not available | $577.20M | $451.60M |
| Mar 31, 2026 | $3.54B | Not available | $551.00M | $387.20M |
| Dec 31, 2025 | $3.52B | Not available | $538.60M | $382.00M |
| Sep 30, 2025 | $3.56B | Not available | $552.40M | $396.60M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $3.73B Jul 30, 2026
- Latest report · revenue estimate
- $3.71B Jul 30, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $3.73B | $3.71B | $4.9900 | $4.7800 |
| Apr 30, 2026 | $3.54B | $3.51B | $4.2500 | $4.1100 |
| Feb 17, 2026 | $3.52B | $3.56B | $4.0700 | $3.9500 |
| Oct 28, 2025 | $3.56B | $3.56B | $4.1800 | $4.1300 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $3.73B | $299M | $3.64 (diluted) |
| Q1 FY2026 | $3.54B | $278M | $3.35 (diluted) |
| Q4 FY2025 | $3.52B | $165M | $1.98 (diluted) |
| Q3 FY2025 | $3.56B | $261M | $3.12 (diluted) |
What are the financial strengths and risks for Labcorp Holdings (LH)?
Short answer
Cash and short-term investments were $141.80M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $445.50M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Labcorp remains profitable and has generated positive operating cash flow throughout the reported sequence, although conversion is uneven and recurring capital expenditure absorbs part of that cash. Liquidity ratios remain above parity, and the quality and distress screens are favorable.
The balance sheet carries substantial debt against a much smaller pool of cash and investments. Readily available cash has fallen sharply across the reported window, leaving operating cash generation more important to financial flexibility; the unchanged dividend also represents a continuing call on capital.
A slowdown in diagnostic activity or pharmaceutical laboratory work would pressure earnings while debt obligations and capital spending remain. That combination makes sustained cash conversion more consequential than an isolated earnings beat.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $445.50M Jun 30, 2026
- Previous quarter · operating cash flow
- $191.50M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $445.50M | −$131.60M |
| Mar 31, 2026 | $191.50M | −$121.00M |
| Dec 31, 2025 | $614.20M | −$123.90M |
| Sep 30, 2025 | $387.20M | −$106.70M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Labcorp Holdings (LH)?
Short answer · as of
The next earnings report is expected on Oct 27, 2026.
Research dated 2026-09-12.
The upcoming earnings release should be read across revenue, gross profit, operating profit, and operating cash flow. Consensus implies modest sequential revenue progress but lower adjusted earnings than the latest reported comparison, so the quality of growth matters as much as clearing the headline estimates.
Watch whether cash rebuilds after its abrupt decline and whether operating cash flow covers capital expenditure with enough room to support debt and shareholder distributions. Progress in Central Labs alongside slower Early Development would align with management's stated mix; weakness across those laboratory activities would challenge it.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
On today's webcast, we will focus on our adjusted or non-GAAP results for the second quarter of 2026, our capital allocation strategy and our updated financial guidance for the full year 2026.
Dewey Steadman ·
We continue to expect our full year adjusted tax rate to be approximately 23%.
Julia Wang ·
We continue to expect free cash flow in the range of $1.24 billion to $1.36 billion for full year 2026.
Julia Wang ·
For the full year, on an organic constant currency basis, we continue to expect Central Labs revenue to grow in the mid-single digits. We now expect Early Development revenue to grow in the low single digits.
Julia Wang ·
How does Labcorp Holdings compare with its peers?
Short answer
Labcorp Holdings's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Labcorp combines high-volume diagnostic services with laboratory work tied to pharmaceutical development. That gives it exposure to patient testing and research programs within the same company, unlike a business concentrated solely in routine clinical diagnostics or solely in outsourced drug-development work.
The trade-off is financial rather than merely operational: this breadth sits alongside meaningful leverage and limited cash relative to debt. Comparisons with similar laboratory businesses therefore need to account for service mix, cash conversion, and financing demands together.
| Company | Price | Market value | Score |
|---|---|---|---|
| $541.70 Oct 2, 2026 | $23.0B | 97 5-pillar Oct 4, 2026 | |
| $85.36 Oct 2, 2026 | $32.2B | 96 5-pillar Oct 4, 2026 | |
| $273.04 Oct 2, 2026 | $41.3B | 94 5-pillar Oct 4, 2026 | |
| $599.47 Oct 2, 2026 | $16.7B | 92 5-pillar Oct 4, 2026 | |
| $518.39 Oct 2, 2026 | $40.9B | 92 5-pillar Oct 4, 2026 | |
| $208.54 Oct 2, 2026 | $20.3B | 87 5-pillar Oct 4, 2026 | |
| $167.77 Oct 2, 2026 | $47.4B | 84 5-pillar Oct 4, 2026 | |
| $1486.19 Oct 2, 2026 | $30.0B | 82 5-pillar Oct 4, 2026 | |
| $233.24 Oct 2, 2026 | $25.7B | 74 5-pillar Oct 4, 2026 | |
| $258.21 Oct 2, 2026 | $42.5B | 73 5-pillar Oct 4, 2026 | |
| Labcorp Holdings (LH) — this page | $308.49 | $25.3B | 71 |
| $151.53 Oct 2, 2026 | $16.9B | 71 5-pillar Oct 4, 2026 | |
| $219.88 Oct 2, 2026 | $32.5B | 67 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $300.00 – $380.00
- Consensus target
- $340.75
- Median target
- $345.00
Consensus record · Captured .
Measured against a quoted price of $308.49 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 1, 2026
- Transactions
- 21
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 9
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 97.2% Period end Jun 30, 2026
- Previous quarter · ownership
- 95.0% Prior to period end Jun 30, 2026
- Reporting holders
- 1,070 Period end Jun 30, 2026
- Previous quarter · holders
- 1,037 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 6,574,261 |
| Vanguard Capital Management LLC | 5,362,254 |
| Victory Capital Management INC | 4,837,573 |
| State Street Corp | 3,907,656 |
| Vanguard Portfolio Management LLC | 3,678,798 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Labcorp Holdings (LH)?
Common Questions About LH (Healthcare)
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
How does Labcorp make money from diagnostics and drug development?
Labcorp earns revenue by providing laboratory services for medical decision-making and for pharmaceutical research. Routine diagnostic activity and drug-development programs therefore feed different parts of the same operating platform.
Why can Labcorp revenue rise while its cash balance falls?
Revenue and accounting profit have increased, but cash also moves with operating conversion, capital expenditure, financing, distributions, and other uses. Recent operating cash flow remained positive while readily available cash contracted sharply, so earnings growth has not translated into cash accumulation.
What matters in Labcorp's Central Labs and Early Development outlook?
Management expects Central Labs to expand faster than Early Development. The relative performance of those activities will indicate whether growth is broad across pharmaceutical laboratory services or concentrated in the stronger operation.
What do Labcorp insider filings show about awards and sales?
Recent activity included sales and transactions classified as awards, in-kind movements, and exempt exercises, with no reported purchases. Those records describe transaction types but do not establish why an insider sold or received shares.
What is the LH stock price today?
The last price recorded on this page for Labcorp Holdings Inc. (LH) is $308.49, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LH price target?
The analyst consensus price target for Labcorp Holdings Inc. (LH) is $340.75 (range $300.00 to $380.00, median $345.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are LH's next earnings?
The next earnings date listed on this page for Labcorp Holdings Inc. (LH) is Oct 27, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (80 figures)
The 80 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Dewey Steadman (Jul 30, 2026): On today's webcast, we will focus on our adjusted or non-GAAP results for the second quarter of 2026, our capital allocation strategy and our updated financial guidance for the full year 2026. Julia Wang (Jul 30, 2026): We continue to expect our full year adjusted tax rate to be approximately 23%. Julia Wang (Jul 30, 2026): We continue to expect free cash flow in the range of $1.24 billion to $1.36 billion for full year 2026. Julia Wang (Jul 30, 2026): For the full year, on an organic constant currency basis, we continue to expect Central Labs revenue to grow in the mid-single digits. We now expect Early Development revenue to grow in the low single digits. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Burlington, NC | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "358 South Main Street, Burlington, NC, 27215, US". |
FMP — 69 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $308.49 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:04:40.090Z. | |
px.change | Change on the day | +1.28% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $25.3B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:02.000Z. Captured from FMP at 2026-10-04T21:04:38.713Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$3.89 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $3.73B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $244.52–$341.80 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 25.35 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 586.9K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.85 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Adam H. Schechter | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 71,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $13.14B, net result $2.38B; FY2022 revenue $11.86B, net result $1.28B; FY2023 revenue $12.16B, net result $418.00M; FY2024 revenue $13.01B, net result $746.00M; FY2025 revenue $13.95B, net result $876.50M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Lab Corp Diagnostics $10.88B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 27.8% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $3.73B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $577.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $451.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $3.54B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $551.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $387.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $3.52B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $538.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $382.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $3.56B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $552.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $396.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-30.revenue_actual | Revenue · reported — report date 2026-07-30 | $3.73B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.revenue_estimated | Revenue · estimate — report date 2026-07-30 | $3.71B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_actual | EPS · reported — report date 2026-07-30 | $4.9900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_estimated | EPS · estimate — report date 2026-07-30 | $4.7800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_actual | Revenue · reported — report date 2026-04-30 | $3.54B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_estimated | Revenue · estimate — report date 2026-04-30 | $3.51B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_actual | EPS · reported — report date 2026-04-30 | $4.2500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_estimated | EPS · estimate — report date 2026-04-30 | $4.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.revenue_actual | Revenue · reported — report date 2026-02-17 | $3.52B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.revenue_estimated | Revenue · estimate — report date 2026-02-17 | $3.56B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_actual | EPS · reported — report date 2026-02-17 | $4.0700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_estimated | EPS · estimate — report date 2026-02-17 | $3.9500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_actual | Revenue · reported — report date 2025-10-28 | $3.56B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_estimated | Revenue · estimate — report date 2025-10-28 | $3.56B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_actual | EPS · reported — report date 2025-10-28 | $4.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_estimated | EPS · estimate — report date 2025-10-28 | $4.1300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $141.80M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $445.50M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $139.30M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $6.77B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 2.93× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $445.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $191.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$131.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$121.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $614.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$123.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $387.20M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$106.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $300.00 – $380.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $340.75 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $345.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 21 transactions · 0 purchases, 9 sales, 12 other transactions · 9 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 97.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 95.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 1,070 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 1,037 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 6,574,261 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 5,362,254 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Victory Capital Management INC — shares in provider snapshot | 4,837,573 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | State Street Corp — shares in provider snapshot | 3,907,656 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 3,678,798 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 27, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-09-14 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-30 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 178.42× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $141.80M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $2.88 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.93% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-30.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($3.73B) with the recorded estimate ($3.71B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-30.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($4.9900) with the recorded estimate ($4.7800) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 71 of 100 · Strong · pillars 79 / 40 / 67 / 56 / 78 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 71 (stored snapshot Oct 3, 2026) → 71 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-30.revenue_actual,earn.history.depth.2026-07-30.revenue_estimated,earn.history.depth.2026-07-30.revenue_actual.comparison,earn.history.depth.2026-07-30.eps_actual.comparison,earn.history.depth.2026-07-30.eps_actual,earn.history.depth.2026-07-30.eps_estimated,earn.history.depth.2026-04-30.revenue_actual,earn.history.depth.2026-04-30.revenue_estimated,earn.history.depth.2026-04-30.eps_actual,earn.history.depth.2026-04-30.eps_estimated,earn.history.depth.2026-02-17.revenue_actual,earn.history.depth.2026-02-17.revenue_estimated,earn.history.depth.2026-02-17.eps_actual,earn.history.depth.2026-02-17.eps_estimated,earn.history.depth.2025-10-28.revenue_actual,earn.history.depth.2025-10-28.revenue_estimated,earn.history.depth.2025-10-28.eps_actual,earn.history.depth.2025-10-28.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Lab Corp Diagnostics: $10.88B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Cash, investments and debt | Total debt: $6.77B; Liquidity basis: cash and short-term investments; Total liabilities: $9.91B; Cash and short-term investments: $141.80M; Cash and investments: $281.10M; Long-term investments: $139.30M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 8071 — Services-Medical Laboratories. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-30 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-30 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $281.10M; Cash and short-term investments: $141.80M; Long-term investments: $139.30M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $141.80M; Decline: $1.38B; Opening balance: $1.52B; Average change per period: $196.50M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$6.62B; Total debt: $6.77B; Cash and investments: $141.80M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.53; Current ratio: 1.8; Debt to equity: 0.79; Net margin: 7%; Gross margin: 27.8%; Operating margin: 11.3%; Return on assets: 5.4%; Return on equity: 11.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 3.35; Piotroski F-score: 8 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-08-28 | FMP | Financial Modeling Prep (FMP) dividend history |
| Next earnings report | Date: 2026-10-27; EPS estimate: $4.65 per share; Revenue estimate: $3.76B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Insider transactions, last 180 days | Net shares: 48,241; Window days: 180; Price low: $209.25; Clustered days: 2026-03-26; 2026-09-01; Price high: $320.37; Buy transactions: 0; Distinct insiders: 13; Sell transactions: 11; Other transactions: 40; Total transactions: 51; Other transaction types: A-Award: 18, F-InKind: 16, M-Exempt: 6; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-09-01 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
| What the sources do not tell us | Captured record · 3 entries
Each entry names a family of information the packet has no fact for.; The list is drawn from a fixed catalogue keyed to fact ids — it is not written per ticker and contains no generated text.; An absent family means our sources did not answer; it does not mean the company has nothing to report. | 2026-09-12 | COMPUTED | Derived from which sources answered this build |
Data provided for informational purposes only.
ETFs that hold LH
Funds in our ETF coverage that list LH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| IHF ETF | 4.05% | |
| Allspring Special Large Value ETF (ASLV) | 3.08% |